129332-29-2

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl (E)-3,5-dihydroxy-7-[3'-(4''-fluorophenyl)-1'-methylethyl-indol-2'-yl]-6-heptenoate is used as a synthetic HMG-CoA reductase inhibitor for antilipemic purposes. It helps in reducing the levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the blood, thus playing a crucial role in the management of hyperlipidemia and cardiovascular diseases.
Used in Drug Synthesis:
Due to its unique molecular structure, tert-Butyl (E)-3,5-dihydroxy-7-[3'-(4''-fluorophenyl)-1'-methylethyl-indol-2'-yl]-6-heptenoate can be used as a key intermediate in the synthesis of various pharmaceutical compounds. Its presence of functional groups such as hydroxyl and heptenoate chain allows for further chemical modifications and the development of new drugs with improved therapeutic properties.
Used in Research and Development:
tert-Butyl (E)-3,5-dihydroxy-7-[3'-(4''-fluorophenyl)-1'-methylethyl-indol-2'-yl]-6-heptenoate can also be utilized in research and development settings to study its potential applications in various fields, such as drug discovery, medicinal chemistry, and biochemistry. Researchers can explore its interactions with biological targets, evaluate its pharmacological properties, and investigate its potential as a lead compound for the development of novel therapeutic agents.

Upstream product

• 375846-25-6 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-5-hydroxy-3-oxo-6-heptenoic acid-1,1-dimethylethyl ester 
• 93957-50-7 3-<3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl>-2(E)-propenal 
• 1694-31-1 tert-butyl acetoacetate 
• 540-88-5 acetic acid tert-butyl ester 
• 194934-95-7 ((S)-(E))-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-5-hydroxy-3-oxo-6-heptenoic acid 1,1-dimethylethyl ester 
• 194934-96-8 (E)-(3R,5S)-(+)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid 1,1-dimethylethyl ester 
• 194934-97-9 ((R)-(E))-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3-hydroxy-5-oxo-6-heptenoic acid 1,1-dimethylethyl ester 
• 194935-00-7 (S-(R*R*)-(E))-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid 1,1-dimethylethyl ester 
• 194935-02-9 ((S)-(E))-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3-hydroxy-5-oxo-6-heptenoic acid 1,1-dimethylethyl ester 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF

The present invention relates to an improved process for the preparation of fluvastatin or pharmaceutical acceptable salts or derivatives thereof, in particular to a one-pot process for large scale production of Fluvastatin and salts thereof in high yield

A PROCESS FOR THE PREPARATION OF FLUVASTATIN SODIUM

An efficient and economical process for preparing Fluvastatin sodium of the formula (I) with high purity and in high yield is disclosed. Further a process for preparing Fluva keto alcohol of the formula (II b) and cyclic boronate complex of the formula (I

An Improved Manufacturing Process for Fluvastatin

An improved manufacturing process for fluvastatin 1 has been developed by performing the condensation reaction of E-[3-(4fluorophenyl)-l-(l-methylethyl)- lH-indol-2-yl]-2-propenal, 4, with the dianion of tert-butyl acetoacetate and the subsequent low-temp

PROCESS FOR PREPARATION OF STATINS WITH HIGH SYN TO ANTI RATIO

Provided is a process for reduction of statin ketoesters and purification of diol esters of the statins through selective crystallization.

PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES BY ENZYMATIC ACYLATION

A process for the preparation of compounds of formula (1), by enzymatic acylation to form compounds of formulae (3a) and (3a') and then reacting the compound of formula (3a) with a compound introducing the radical of formula -CH2-COOR8

Process for the preparation of indole derivatives and intermediates of the process

A process for the preparation of compounds of formula (1), wherein R1 is C1-C6alkyl and X is hydrogen, a hydrocarbon radical or a cation, wherein a compound of formula (2), wherein R1 is as defined above and Rs

Asymmetric synthesis of 3,5-dihydroxy-6(E)-heptenoate-containing HMG-CoA reductase inhibitors

A 'one-pot' conversion of aldehyde 6 to hydroxyketoester 10 with high enantioselection, culminating in a practical asymmetric synthesis of (3R,5S) isomer of the antihyperlipoproteinemic agent fluvastatin, 1, is described. All four 3,5-dihydroxy-6(E)-heptenoate stereoisomers were prepared in enantiopure form starting from 10, utilizing selective reduction and oxidation methods.